Suppr超能文献

高剂量雷贝拉唑和阿莫西林联合治疗与雷贝拉唑、阿莫西林和甲硝唑三联疗法作为标准三联疗法后幽门螺杆菌感染的挽救方案。

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.

作者信息

Shirai Naohito, Sugimoto Mitsushige, Kodaira Chise, Nishino Masafumi, Ikuma Mutsuhiro, Kajimura Masayoshi, Ohashi Kyoichi, Ishizaki Takashi, Hishida Akira, Furuta Takahisa

机构信息

Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

出版信息

Eur J Clin Pharmacol. 2007 Aug;63(8):743-9. doi: 10.1007/s00228-007-0302-8. Epub 2007 Jun 13.

Abstract

BACKGROUNDS AND AIMS

Development of safe and effective rescue regimens for eradication failure of Helicobacter pylori infection by standard regimens is an urgent task. We designed the prospective study to compare the efficacy of two rescue regimens after eradication failure by the standard triple therapy.

METHODS

One hundred and thirty-two patients in whom eradication of H. pylori infection failed initial triple therapy with lansoprazole 30 mg b.i.d, amoxicillin 750 mg b.i.d. and clarithromycin 400 mg b.i.d. for 1 week were randomized to either the 1-week triple therapy with rabeprazole 10 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d. (RAM) or the 2-week dual therapy with rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. (RA). Eradication of H. pylori was judged by (13)C-urea breath test 1 month later.

RESULTS

The intention-to-treat and per-protocol-based eradication rates were 92.4% (95% CI: 83.2-97.5) and 95.3% (95% CI: 86.9-99.0) for the RAM therapy and 90.9% (95% CI: 81.2-96.6) and 93.8% (95% CI: 84.8-98.3), respectively, for the RA therapy (P > 0.2 for both). No clinically recognizable adverse events were observed with either regimen.

CONCLUSION

RA as well as RAM therapy are safe and effective rescue regimens for H. pylori infection after eradication failure by the standard triple therapy.

摘要

背景与目的

针对标准疗法根除幽门螺杆菌感染失败的情况,开发安全有效的补救方案是一项紧迫任务。我们设计了这项前瞻性研究,以比较标准三联疗法根除失败后两种补救方案的疗效。

方法

132例患者初始采用兰索拉唑30 mg,每日2次、阿莫西林750 mg,每日2次、克拉霉素400 mg,每日2次的三联疗法治疗1周后,幽门螺杆菌感染根除失败,将其随机分为两组,一组接受雷贝拉唑10 mg,每日2次、阿莫西林750 mg,每日2次、甲硝唑250 mg,每日2次的1周三联疗法(RAM),另一组接受雷贝拉唑10 mg,每日4次、阿莫西林500 mg,每日4次的2周双联疗法(RA)。1个月后通过¹³C-尿素呼气试验判断幽门螺杆菌的根除情况。

结果

RAM疗法的意向性治疗和符合方案分析的根除率分别为92.4%(95%CI:83.2-97.5)和95.3%(95%CI:86.9-99.0),RA疗法分别为90.9%(95%CI:81.2-96.6)和93.8%(95%CI:84.8-98.3)(两者P均>0.2)。两种方案均未观察到临床上可识别的不良事件。

结论

对于标准三联疗法根除失败后的幽门螺杆菌感染,RA疗法和RAM疗法都是安全有效的补救方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验